- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06072430
VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients (VBI-S-02) (VBI-S-02)
VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
STUDY TREATMENT Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs. When hypotension due to sepsis cannot be reversed with the infusion of fluids the patient is in a state of septic shock. Septic shock is therefore an acute medical emergency and delayed therapy can lead to organ injury. VBI-S is intended to raise blood pressure in patients with septic shock.
Randomization and blinding: This is an open label study, randomization and blinding are not applicable to this study. All patients entering this study will be treated with VBI-S.
Data Safety Monitoring Board: A Data Safety Monitoring Board (DSMB) will review the study data.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Cuthbert O Simpkins, MD, FACS
- Phone Number: 3187711294
- Email: cuthbert@vivacellebio.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female at least 18 years of age.
- Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection and/or an elevated procalcitonin of ≥ 2 ng/ml.
- Patient has a mean blood pressure < 65 mmHg that is unresponsive to fluids currently available on the market.
- Sequential Organ Failure Assessment (SOFA) score ≥ 5 and ≤ 11 with the maximum SOFA score of 24.
- Failure of standard therapy defined as no decrease in the SOFA score for 48 hours or a SOFA score > 11 on admission to the ICU.
Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:
- Lactate > 2 mmol/L
- Fever > 38.3°C, or 101°F
- Hypothermia < 36°C core temperature (<96.8°F)
- Heart rate > 90
- Tachypnea (respiratory rate ≥ 20/min)
- White blood cell count >12,000 or less than 4,000, or with >10% "bands" (immature forms)
- Elevated procalcitonin in serum (≥ 2ng/ml)
- Arterial hypoxemia (PaO2/FiO2 < 300)
- Creatinine increase > 0.5 mg/dL
- INR > 1.5 or aPTT > 60 seconds
Exclusion Criteria:
- Patients with a ventricular assist device
- Acute coronary syndrome
- Pregnant
- Acute bronchospasm
- Acute Mesenteric ischemia
- Emergency major surgery
- Diagnosis of acute Hepatitis B or C
- Hematologic or coagulation disorders including thrombocytopenia (platelet count < 50,000) and associated with hemodynamically significant active bleeding that causes a decrease in blood pressure
- White blood cell count of < 1000 mm3
- Current participation or participation in another experimental or device study with the last 30 days before the start of this study. Patient may be included if on other drugs for COVID-19
- Patients with a known allergy to soybeans or eggs
- Patient is hypervolemic as assessed by ultrasound
- Patient expected to expire within 12 hours
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VBI-S
Treatment with VBI-S
|
VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Elevation in Average Mean Arterial Pressure
Time Frame: 10 months
|
The primary endpoint is defined as an elevation in average mean arterial pressure by at least 10 mmHg.
|
10 months
|
Adverse Drug Reactions
Time Frame: 10 months
|
The number of patients with adverse drug reactions.
|
10 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Blood Pressure Increase
Time Frame: 10 months
|
The number of patients in whom mean blood pressure increased by at least 10 mmHg.
|
10 months
|
Dose of Pressor Drugs
Time Frame: 10 months
|
The number of patients in whom the dose of pressor drugs could be decreased after infusion of VBI-S to maintain a mean arterial pressure of 60-65 mmHg.
|
10 months
|
Ratio of Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen
Time Frame: 10 months
|
Change in ratio of partial pressure of oxygen in arterial blood/Fraction of inspired oxygen (P/F ratio).
|
10 months
|
Arterial Oxygen Saturation
Time Frame: 10 months
|
Change in arterial oxygen saturation.
|
10 months
|
Partial Pressure of Oxygen
Time Frame: 10 months
|
Change in partial pressure of oxygen.
|
10 months
|
Arterial Blood pH
Time Frame: 10 months
|
Change in arterial blood pH.
|
10 months
|
Arterial Blood Base Excess
Time Frame: 10 months
|
Change in arterial blood base excess.
|
10 months
|
Arterial Blood Carbon Dioxide
Time Frame: 10 months
|
Change in arterial blood carbon dioxide.
|
10 months
|
Sequential Organ Failure Assessment (SOFA) Score
Time Frame: 10 months
|
Change in Sequential Organ Failure Assessment (SOFA) Score on a scale of 0 to 24.
A higher score indicates a worse outcome.
|
10 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cuthbert O Simpkins, MD, FACS, Vivacelle Bio
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VBI-S-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
-
Inverness Medical InnovationsCompletedSepsis | Systemic Inflammatory Response Syndrome | Severe Sepsis | Sepsis SyndromeUnited States
Clinical Trials on VBI-S
-
Vivacelle BioActive, not recruitingSepsis | Septic Shock | HypovolemiaUnited States
-
VBI Vaccines Inc.Clinical Trial Data Services, LLCCompletedCytomegalovirus InfectionsCanada
-
VBI Vaccines Inc.Completed
-
VBI Vaccines Inc.Active, not recruitingCoronavirus Infections | COVID-19Canada
-
Brii Biosciences LimitedVBI Vaccines Inc.; Vir Biotechnology, Inc.CompletedHepatitis B, ChronicAustralia, China, Korea, Republic of, New Zealand, Singapore, Thailand
-
VBI Vaccines Inc.WithdrawnCoronavirus Infections | COVID-19Canada
-
NHS Greater Glasgow and ClydeUniversity of GlasgowUnknownAlcohol Consumption | Violence | Facial InjuriesUnited Kingdom
-
Shiga UniversityUniversity of Chicago; Shionogi; Tokyo University; Showa University; Fukushima Medical... and other collaboratorsUnknown
-
Boston Scientific CorporationCompletedTachycardia, VentricularUnited Kingdom, Denmark, Italy, New Zealand, Germany, France, Netherlands, Portugal, Czechia, Spain
-
VBI Vaccines Inc.RecruitingGlioblastoma MultiformeUnited States